Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Becherini C, et al. Among authors: marangoni e. Cancer Treat Rev. 2023 Sep;119:102586. doi: 10.1016/j.ctrv.2023.102586. Epub 2023 Jun 15. Cancer Treat Rev. 2023. PMID: 37336117 Free article. Review.
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A, Iravani M, El-Botty R, Alexander J, Sourd L, Morisset L, Painsec P, Orha R, Nikitorowicz-Buniak J, Pancholi S, Haider S, Dowsett M, Marangoni E, Martin LA, Isacke CM. Soosainathan A, et al. Among authors: marangoni e. Cancer Res. 2024 Jan 2;84(1):17-25. doi: 10.1158/0008-5472.CAN-23-0650. Cancer Res. 2024. PMID: 37801608 Free PMC article.
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer.
Bacci M, Lorito N, Smiriglia A, Subbiani A, Bonechi F, Comito G, Morriset L, El Botty R, Benelli M, López-Velazco JI, Caffarel MM, Urruticoechea A, Sflomos G, Malorni L, Corsini M, Ippolito L, Giannoni E, Meattini I, Matafora V, Havas K, Bachi A, Chiarugi P, Marangoni E, Morandi A. Bacci M, et al. Among authors: marangoni e. Sci Transl Med. 2024 Feb 28;16(736):eadf9874. doi: 10.1126/scitranslmed.adf9874. Epub 2024 Feb 28. Sci Transl Med. 2024. PMID: 38416843
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Cottu P, et al. Among authors: marangoni e. Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16. Breast Cancer Res Treat. 2012. PMID: 22002565
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T. Maire V, et al. Among authors: marangoni e. Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9. Cancer Res. 2013. PMID: 23144294
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.
Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, Mazzone M, Chiarugi P, Morandi A. Bacci M, et al. Among authors: marangoni e. Cell Rep. 2019 Jul 2;28(1):104-118.e8. doi: 10.1016/j.celrep.2019.06.010. Cell Rep. 2019. PMID: 31269432 Free PMC article.
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, Lorito N, Sourd L, Huguet L, Dahmani A, Painsec P, Derrien H, Vacher S, Masliah-Planchon J, Raynal V, Baulande S, Larcher T, Vincent-Salomon A, Dutertre G, Cottu P, Gentric G, Mechta-Grigoriou F, Hutton S, Driouch K, Bièche I, Morandi A, Marangoni E. El-Botty R, et al. Among authors: marangoni e. Nat Commun. 2023 Jul 14;14(1):4221. doi: 10.1038/s41467-023-40022-5. Nat Commun. 2023. PMID: 37452026 Free PMC article.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, D'Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin-Gutierrez P, Moss TA, Maglennon G, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, Sánchez-Guixé M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS. Lawson M, et al. Among authors: marangoni e. Cancer Res. 2023 Dec 1;83(23):3989-4004. doi: 10.1158/0008-5472.CAN-23-0694. Cancer Res. 2023. PMID: 37725704 Free PMC article.
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.
de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E. de Plater L, et al. Among authors: marangoni e. Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877358 Free PMC article.
199 results